India-based Ranbaxy Laboratories has reportedly agreed to settle claims that that the manufacturing process for its prescription drugs sold in Oregon failed to comply with federal good manufacturing practices thus violating state consumer protection and pharmacy laws. Oregon Attorney General Ellen Rosenblum said, “Fortunately, no Oregonians are known to have been harmed from these common generic drugs, and all of the products are now off the market.” The agreement, worth $2.3 million, requires payments to five Oregon state agencies—the Public Employees Benefits Board, Oregon Department of Corrections, State Accident Insurance Fund Corp., Oregon Youth Authority, and Oregon Health Authority. The company must also make a payment to the state consumer protection fund and the Board of Pharmacy. See Oregon Department of Justice Press Release, July 8, 2014.